Fuso Pharmaceutical Industries
Basic Information
- Stock Code
- 4538
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Osaka Prefecture
- Establishment Year
- March 1937
- Listing Year
- October 1970
- Official Website
- https://www.fuso-pharm.co.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- Kyowa Kirin, Takeda Pharmaceutical, Astellas Pharma, Shionogi, Chugai Pharmaceutical, Eisai, Ono Pharmaceutical, Santen Pharmaceutical, Towa Pharmaceutical, Daiichi Sankyo, Otsuka Holdings, Sawai Group HD, Sankyo Chemical
Overview
Fuso Pharmaceutical Industries is a pharmaceutical manufacturer founded in 1937, boasting the top market share in dialysis-related products and actively focusing on infertility treatments, as a leading company based in Osaka Prefecture.
Current Situation
Fuso Pharmaceutical Industries recorded net sales of 55.47 billion yen, operating income of 1.964 billion yen, and net income of 1.377 billion yen for the fiscal year ended March 2024, maintaining a solid financial foundation. Its core business is manufacturing dialysis fluids for human hemodialysis, holding the top domestic market share, while also boasting high market occupancy in infusions and injectables. It is actively pursuing research and development in infertility treatment-related products to strengthen competitiveness in the medical pharmaceuticals sector. In recent years, it has focused on expanding manufacturing equipment at the Ibaraki Plant and developing new products to differentiate from competitors. It has also reorganized its business through responses to patent infringement lawsuits and transfers of sales rights, optimizing its business portfolio. As part of sustainability initiatives, it promotes environmental burden reduction and regional contributions, aiming for long-term growth. Moving forward, it plans to continue investments in medical devices and advanced pharmaceuticals to expand its business in response to medical needs domestically and internationally.
Trivia
Interesting Facts
- One of the first companies in Japan to develop dialysis fluid for artificial kidneys.
- Holds the top brand in dialysis concentrates meeting medical needs.
- One of Japan's leading manufacturers of IVF culture media.
- Expands business not only in pharmaceuticals but also medical devices.
- Head office building in Dojima, Chuo-ku, Osaka, located in the pharmaceutical district.
- Full entry into infertility treatment product development since 2000.
- Past sponsor of Downtown DX.
- History of receiving large compensation orders in patent infringement cases.
- Large-scale production factory in Kita-Ibaraki City, Ibaraki Prefecture.
- Stable shareholder composition through employee stock ownership plan.
- Listed on both Osaka Stock Exchange Section 1 and Tokyo Stock Exchange Section 1.
- "Fuso" brand known in the dialysis fluid market.
- Supports regional medicine through multiple branches and sub-offices nationwide.
- Boasts high-quality control technology honed through long years of pharmaceutical manufacturing.
- Product sales rights transfer cases attracting attention in the industry.
Hidden Connections
- No relation to Fuso Chemical Industry, another chemical company in the same Chuo-ku, Osaka City.
- Medical blood purifiers are co-sold products with Kaneka Medix, indicating strong collaboration.
- Multiple relationships with pharmaceutical makers like Toray Pharmaceutical and Kobayashi Pharmaceutical through long-term transactions.
- Deep ties with Sawai Group in patent litigation, creating a fierce competitive environment.
- President Toda Mikio is also a major shareholder, linking management and investment.
- Head office in Joto-ku, Osaka City, is close to factories for tight integration with manufacturing sites.
- Close collaboration with local medical institutions, with branches expanding nationwide.
- Post-Great East Japan Earthquake, Ibaraki Plant equipment strengthening includes disaster prevention measures.
Future Outlook
Growth Drivers
- Increase in dialysis patients due to domestic aging population
- Expansion of IVF and infertility treatment market
- Advancement and普及 of medical device products
- Efficiency in production technology and product quality improvement
- Market environment changes from regulatory easing and drug price revisions
- Trends toward overseas medical market entry
- Accelerated new product development through digitalization
- Strengthened response to ESG management
- Opportunities for entry into new medical fields
- Flexibility to meet diversifying medical needs
- Maintaining technological superiority through patent portfolio utilization
- Strengthened collaboration with joint R&D partners
Strategic Goals
- Maintain domestic dialysis fluid share and expand overseas
- Improve market share in infertility treatment-related products
- Promote new product development in medical devices
- Realize sustainable manufacturing processes
- Enhance corporate value in line with ESG metrics
- Strengthen patent rights and advance IP strategy
- Company-wide DX promotion for business efficiency
- Build collaboration systems with domestic and international medical institutions
- Foster employee diversity and comfortable workplace environment
- Strengthen CSR activities for coexistence with local communities
Business Segments
Medical Pharmaceutical Manufacturing
- Overview
- Manufactures dialysis fluids and injections for medical institutions, ensuring stable supply.
- Competitiveness
- High share and technological prowess in the dialysis fluid market
- Customers
-
- Hospitals
- Medical institutions
- Wholesalers
- Testing research institutions
- Dialysis facilities
- Pharmaceutical companies
- Products
-
- Artificial kidney dialysis fluid
- Injections
- Diagnostic drugs
- Blood purifiers
- Research reagents
IVF and Reproductive Assistance Medical
- Overview
- Provides specialized medical products such as culture media for infertility treatment.
- Competitiveness
- Leading domestic high-quality culture media development technology
- Customers
-
- Infertility treatment clinics
- Reproductive medical facilities
- Research institutions
- Products
-
- Culture media
- Related medical devices
Medical Devices and Equipment Supply
- Overview
- Develops and sells advanced medical devices to support medical sites.
- Competitiveness
- Expanded product lineup through co-sales
- Customers
-
- Hospitals
- Medical institutions
- Testing centers
- Products
-
- Blood purifiers
- Myocardial protection solutions
- Infusion products
Pharmaceutical Contract Manufacturing (OEM)
- Overview
- Provides contract manufacturing services for other companies' pharmaceutical products.
- Competitiveness
- Abundant manufacturing expertise and high-quality control
- Customers
-
- Pharmaceutical companies
- Biotech ventures
- Medical device manufacturers
- Products
-
- Injections
- Infusions
- In vitro diagnostic drugs
Logistics and Distribution Services
- Overview
- Supports efficient product supply to medical institutions.
- Competitiveness
- Stable pharmaceutical distribution network
- Customers
-
- Pharmaceutical wholesalers
- Hospitals
- Pharmacies
- Products
-
- Product delivery
- Warehouse management
Competitive Advantage
Strengths
- Domestic top-tier dialysis fluid share
- Advanced manufacturing technology and quality control
- Long track record in pharmaceutical manufacturing
- Diverse medical pharmaceutical lineup
- Specialized technology in infertility treatment
- Dedicated R&D organization
- Stable supply chain
- Nationwide network of regional bases
- Strategic patent management
- Strong financial base
- Advanced regulatory compliance capabilities
- Product expansion through co-sales
- Competitive enhancement via technology partnerships
- Business expansion into medical devices
- Long-term corporate brand reliability
Competitive Advantages
- Leadership and technological superiority in the dialysis fluid market
- High market position in medical infusions and injectables manufacturing
- Expertise and early market entry in infertility treatment products
- Production efficiency and quality improvement through in-house factories
- Broad sales channels and strong customer base
- Patent strategy that appropriately manages litigation risks
- Diversified business development in medical devices
- Advanced R&D investments and innovation capabilities
- Customer satisfaction improvement through regional close-knit services
- Stable cash flow and capital structure
- Strong relationship building with Ministry of Health, Labour and Welfare
- Production and sales network via multiple factories and branches
- Product design attuned to medical site needs
- Proprietary powdered dialysis concentrate manufacturing technology
- Trusted brand image in the industry
Threats
- Damage compensation risks from patent infringement lawsuits
- Intensified competition due to generics makers' market restructuring
- Stricter regulations on pharmaceuticals and medical devices
- Vulnerability of revenue structure dependent on specific markets
- Demand fluctuations from demographic changes
- Rising raw material costs from exchange rate fluctuations
- Market share pressure from new entrants
- Decline in competitiveness from technological stagnation
- Price suppression pressure from medical policy changes
- Supply chain disruption risks
- Production base damage from natural disasters
- Increased costs for intellectual property infringement responses
Innovations
2024: Expansion of Powdered Dialysis Concentrate Manufacturing Equipment at Ibaraki Plant
- Overview
- Expanded powdered dialysis concentrate manufacturing equipment in the second formulation building at Ibaraki Plant to increase production capacity.
- Impact
- Contributes to improved production efficiency and supply stability
2022: Transition to Tokyo Stock Exchange Prime Market
- Overview
- Shifted market segment from Section 1 to Prime Market to enhance corporate value.
- Impact
- Increased attention and trust from investors
2020: Strengthened Development of Culture Media Products for Infertility Treatment
- Overview
- Expanded IVF-related products like HiGROW series to strengthen market competitiveness.
- Impact
- Expanded share in reproductive assistance medical field
2021: Business Reorganization Related to Patent Infringement Litigation Response
- Overview
- Implemented sales rights transfers and business reorganization for patent infringement issues to manage risks.
- Impact
- Suppressed damage compensation costs and improved business health
2023: Advancement of Powdered Dialysis Concentrate Technology Development
- Overview
- Pursued new technology development in dialysis concentrate manufacturing to improve product quality and safety.
- Impact
- Further strengthened product competitiveness
2024: Expansion of Co-Sales System in Medical Devices
- Overview
- Expanded medical devices business through co-sales of adsorptive blood purifiers.
- Impact
- Expanded product lineup and increased market share
Sustainability
- Implementation of measures to reduce environmental impact in production processes
- Participation in environmental conservation activities for local communities
- Promotion of pharmaceutical recycling activities
- Strengthening employee safety and health activities
- Providing resource-efficient products to medical sites
- Formulation of sustainable procurement policies
- Promotion of women's empowerment and diversity
- Strengthening Environment, Social, Governance (ESG)
- Ongoing commitment to regional medical support activities
- Compliance with laws and ensuring transparency